Form 4: Aclarion Director Receives Equity Grant

Director Stephen Deitsch was granted 20,000 restricted stock units in Aclarion, Inc. as part of the company's equity incentive plan.

Summary

• Director Stephen Deitsch acquired 20,000 restricted stock units (RSUs) on June 11, 2026.
• Each RSU represents a contingent right to receive one share of Aclarion, Inc. (ACON) common stock.
• The grant was issued under the company's existing equity incentive plan.
• The RSUs are scheduled to vest in full on June 1, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• Potential for future shareholder dilution upon the vesting and issuance of the underlying common stock.

Risks

• Vesting is subject to continued service, and the value of the equity is dependent on future stock performance.

Future Outlook

The RSUs will vest on June 1, 2027, or earlier in the event of a change of control as defined by the company's equity incentive plan.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices intended to incentivize long-term oversight and alignment with shareholder value.

Comparison to Industry Standards

• The use of RSU grants for board compensation is consistent with standard practices for small-cap technology and healthcare companies.
• Vesting schedules of approximately one year for director equity are common in the industry.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual conversion of RSUs to common stock.

Next Steps

• Vesting of 20,000 RSUs on June 1, 2027.

Key Dates

Keywords

Aclarion, ACON, Form 4, Insider Trading, Equity Incentive Plan, Restricted Stock Units